PLA allows specific protein complexes to be visualized and measured in cancer specimens. This may aid in patient treatment decisions in the future.
Clinical researchers and physicians often rely on measurements of cancer biomarkers as diagnostic, prognostic or treatment indicators. Cancer biomarkers are biological characteristics of tumors, such as genetic mutations, protein expression levels or protein modification events. Current biomarker analysis primarily focuses on single genes or proteins. However, proteins do not function on their own; rather, they are often part of larger multi-protein complexes and can interact with many different proteins. By only using single proteins as biomarkers, clinicians may not have an accurate description of what is actually occurring within a tumor.
Moffitt researchers developed the PLA approach in cancer specimens to analyze protein complexes and allow a better understanding of the events that occur in cancer. They focused their study on the epidermal growth factor receptor (EGFR) that is often mutated or expressed at high levels in many tumor types, including non-small cell lung cancer, head and neck squamous cell carcinoma, and renal cell carcinoma. They discovered that lung cancer patients who were treated with EGFR inhibitors and had high amounts of EGFR protein complexes had a better prognosis.
These protein complexes may become new biomarkers to help physicians diagnose and treat patients with a certain class of drugs called receptor tyrosine kinase inhibitors. Protein complex analysis by PLA may also help physicians determine how patients become resistant to these drugs.
This work was the first step in the assessing therapy relevant protein complexes in cancer specimens. “We show that it is feasible to build assays that reflect protein complexes in cancer cells and these assays are associated with drug sensitivity. Our lab is developing additional assays reflecting protein complexes relevant to cancer therapeutics and we envision the ability to use these assays to help make therapeutic decisions for our patients,” said Eric B. Haura, M.D., director of the Lung Cancer Center of Excellence at Moffitt.
“We think this is an exciting new way to look at targetable signaling activity in cancer cells. If we can figure out which molecular pathways are activated, we will be better able to match patients to available targeted therapies and hopefully improve outcomes,” said Matthew A Smith, Ph.D., MSPH, post-doctoral fellow at Moffitt.
This study was published in the Jan. 13 issue of Science Signaling and will be discussed in a podcast on the Science Signaling website. The research was supported by grants from the National Cancer Institute (P50-CA119997 and R21 CA162178) and partly by a fellowship from the Lung Cancer Research Foundation.
About Moffitt Cancer Center
Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the top-ranked cancer hospital in the Southeast and has been listed in U.S. News & World Report’s “Best Hospitals” for cancer since 1999. With more than 4,500 employees, Moffitt has an economic impact on Florida of nearly $1.6 billion. For more information, visit MOFFITT.org, and follow the Moffitt momentum on Facebook, Twitter and YouTube.